drugset / Trial / NCT00862472

Safety and Efficacy Study of DuoTrav APS Versus DuoTrav

NCT00862472

Phase 3 Withdrawn Alcon Research
RandomizedParallel-groupDouble-blindTreatment

Summary

The purpose of the study is to demonstrate that the IOP-lowering efficacy of DuoTrav APS, dosed once-daily in the morning, is non-inferior to that of DuoTrav, dosed once-daily in the morning.

Timeline

Start
2009-03
Primary completion
2009-06
Completion
2009-06

Drugs

EvaluationDrugModalityDoseRoute
Comparator DuoTrav Unknown
Subject DuoTrav APS Unknown